Literature DB >> 8444178

Glycerophosphocholine release in human erythrocytes. 1H spin-echo and 31P-NMR evidence for lysophospholipase.

H Selle1, B E Chapman, P W Kuchel.   

Abstract

The direct techniques of 1H spin-echo and 31P-NMR spectroscopy made it possible to monitor the release of glycerophosphocholine from lysophosphatidylcholine in lysates from human red blood cells. Thus, the existence of a lysophospholipase in human erythrocytes was confirmed using a new more direct method. No evidence for a phospholipase A2 activity in the haemolysates was found with the same approach; since this enzyme is present in leukocytes, the absence of activity helped verify the purity of the erythrocyte preparation. The lysophospholipase may constitute, with the earlier described glycerophosphocholine phosphodiesterase activity, a metabolic unit for the removal of haemolytic lysophosphatidylcholine which is formed in the erythrocyte membranes as well as taken up from the plasma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444178     DOI: 10.1111/j.1432-1033.1993.tb17676.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  3 in total

1.  Quantitative 31P nuclear magnetic resonance analysis of the phospholipids of erythrocyte membranes using detergent.

Authors:  M H Nouri-Sorkhabi; L C Wright; D R Sullivan; P W Kuchel
Journal:  Lipids       Date:  1996-07       Impact factor: 1.880

2.  Lysophosphatidylcholine hydrolases of human erythrocytes, lymphocytes, and brain: sensitive targets of conserved specificity for organophosphorus delayed neurotoxicants.

Authors:  Sarah C Vose; Nina T Holland; Brenda Eskenazi; John E Casida
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-27       Impact factor: 4.219

3.  Metabolomics coupled with pathway analysis characterizes metabolic changes in response to BDE-3 induced reproductive toxicity in mice.

Authors:  Ziheng Wei; Jing Xi; Songyan Gao; Xinyue You; Na Li; Yiyi Cao; Liupeng Wang; Yang Luan; Xin Dong
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.